Purdue Pharma knew OxyContin was highly addictive but marketed it as safe

OxyContin: When a Pharmaceutical Company Knew Better

In the 1990s, Purdue Pharma released OxyContin with a promise that seemed almost too good to be true: a powerful painkiller that would relieve suffering without the addiction risk of older opioids. Doctors embraced it. Patients sought it out. The company's sales force fanned across America's medical offices with a simple message: this drug was safe. Within a decade, it became clear that message was a lie.

The claim that Purdue Pharma knowingly misrepresented OxyContin's addiction potential wasn't initially taken seriously by everyone. When addiction rates spiked in the early 2000s, the company maintained its public position: improper use by patients was the problem, not the drug itself. They suggested that people became addicted because they weren't following directions, because they were drug-seekers, because they had addictive personalities. The official narrative blamed the users, not the product.

But documents revealed through litigation told a different story. Internal Purdue communications showed that executives and researchers understood OxyContin's dangers long before the public did. Company scientists had data demonstrating the drug's high addiction potential. Sales representatives were trained to downplay these risks to doctors. Marketing materials minimized addiction concerns while exaggerating pain relief benefits. The company even paid doctors to give talks promoting OxyContin to their peers, knowing full well what the internal research showed.

A particularly damning detail emerged from court filings: Purdue's own medical affairs department had flagged addiction concerns years before the company faced public scrutiny. Yet these warnings never made it into the marketing materials that physicians received. Instead, the company's messaging stuck to claims about low abuse potential—claims they knew were contradicted by their own research.